Company intelligence / Profile preview
Sanaregen Vision Therapeutics
United Statessanaregenvision.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Sanaregen Vision Therapeutics develops affordable and accessible regenerative therapies aimed at restoring vision in patients with debilitating retinal diseases. Their pipeline targets drusen-related conditions such as Familial Drusen and advanced Geographic Atrophy. The company leverages over a century of combined expertise in neuroscience, regulatory affairs, patient advocacy, and retinal research to address unmet needs in ophthalmology. Clinical results are not yet published; the company appears focused on preclinical development through 2027.[1]
- Therapeutic areas
- Rare DiseasesOphthalmology
- Modalities
- Cell-based therapiesregenerative medicine[1]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Partners aligned toward improving vision outcomes for rare or underserved conditions; specific partner names not disclosed.[1]
Beyond the preview
Go deeper on Sanaregen Vision Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanaregen Vision Therapeutics.